Souhaitez-vous accéder aux communiqués récents ?

XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass...

Press release – No. 13 / 2026  New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...

Eupraxia Pharmaceuticals Reports Initial One Year Clinical Results from RESOLVE Trial in Patients with Eosinophilic Esophagitis (EoE).

Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science,...

Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period...

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary...

Freiburg, den 7. Mai 2025 Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes Arzneimittel...

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS)Research Finds Patients Following a Personalized Diet Therapy Created with inFoods® IBS,...